Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

NewCardio To Launch CardioBip At HRS Annual Meeting

NewCardio, a cardiac diagnostic technology provider, expects to unveil its patented CardioBip technology for remote wireless 12-lead detection and monitoring of atrial fibrillation, ischemia and other cardiovascular events at the Heart Rhythm Society (HRS) 31st Annual Scientific Sessions, in Denver, Colorado.

According to the company, in addition to launch, NewCardio personnel will demonstrate the CardioBip, both at the company’s booth and on a suite at the Hyatt Regency Denver, adjacent to the Denver Convention Ctr where HRS is held. Also HRS has accepted an abstract detailing the superior performance of NewCardio’s CardioBip, particularly in patients with atrial fibrillation for its oral presentation.

The CardioBip is a unique, hand-held device that provides a solution for ECG remote monitoring. Patients can carry the CardioBip with them and use it to generate and transmit synthesized, accurate 12-lead ECGs at physician prescribed intervals of time, during ordinary daily activity or when symptoms develop.

NewCardio claimed that the CardioBip is unique because of its extreme ease of use, combined with the ability to generate recordings substantially equivalent in quality with standard 12-lead ECGs.

The CardioBip works without any cables, cumbersome leads, wires or inconvenient skin electrodes, as the device’s electrodes are integrated, offering potential compatibility with popular hand-held PDA platforms. The device is not currently approved for sale or distribution in the US.

Reportedly, on January 12, 2010, the US Patent and Trademark Office issued patent 7,647,093, titled ‘Apparatus and method for cordless recording and telecommunication transmission of three special ECG leads and their processing.’ This represents the core patent for CardioBip. Additional patent applications covering the CardioBip have been submitted.

Branislav Vajdic, CEO of NewCardio, said: “CardioBip is the first remote, wireless, non-invasive device which provides accurate 12-lead ECG results, and as such we believe it will propel remote cardiac monitoring to an entirely new level.

‚ÄúThis is the culmination of several years of work to advance this technology, and we are excited to share this significant clinical and technological advancement with scientists, medical professionals and industry leaders at the HRS Annual Scientific Sessions. With its 3-D technology, CardioBip will provide important data that addresses significant problems with the diagnosis and treatment of chronic cardiac conditions.”